AbbVie and MBC BioLabs Team Up to Support Life-Science Startups in the San Francisco Bay Area

One Bench at a Time

AbbVie and MBC BioLabs Team Up to Support Life-Science Startups in the San Francisco Bay Area

Read press release at CISION PR Newswire

San Francisco, CA February 5, 2018 – AbbVie, a global biopharmaceutical company, and MBC BioLabs (formerly known as QB3@953), a life-science incubator, announced that they have teamed up to help support and mentor promising startups.  The partnership provides AbbVie multiple ways to access and support companies in the MBC BioLabs community – including allocating “Golden Tickets”, which offers entrepreneurial scientists one year’s use of a lab bench and core facilities at MBC BioLabs’ San Francisco or San Carlos site.

MBC BioLabs and AbbVie have a successful track record of collaboration.  AbbVie Ventures, the private investing arm of AbbVie, has invested in startups from MBC BioLabs’ ecosystem, including Alector and eFFECTOR.  Investing since 2009, AbbVie Ventures focuses exclusively on novel, transformational therapeutics at discovery and pre-clinical stages across oncology, immunology and neuroscience.

“AbbVie is focused on developing medical treatments that address some of the most complex health challenges across immunology, oncology and neuroscience,” said Tom Hudson, M.D., vice president, oncology discovery and early development and head, research and development, Redwood City, AbbVie. “AbbVie and AbbVie Ventures seek tomorrow’s innovators and the Bay Area is a primary center of scientific talent.  Partnering our broad local resources, including more than 1,000 researchers and active venture investing, with MBC BioLabs’ proven capabilities to identify and nurture promising innovation, will help turn today’s science into tomorrow’s therapies.”

“MBC BioLabs’ innovative approach radically lowers the cost and time required to launch a biotech startup, allowing entrepreneurial scientists to turn their ideas into tomorrow’s scientific breakthroughs,” said MBC BioLab’s General Manager, Doug Crawford.  “An important part of our contribution to their success is to build a rich community of entrepreneurs, investors, and strategic partners.  We want to narrow the gap between the biggest and smallest life-science companies.  We are thrilled to have AbbVie join this mission.”

About MBC BioLabs
MBC BioLabs provides space as small as a single bench in fully-equipped labs.  Scientists can conduct experiments on their first day, cutting months and millions of dollars off the time and cost necessary to gather data.   MBC BioLabs’ facilities in San Francisco and San Carlos are home to 45 energetic young companies.  Since opening its doors four years ago, MBC BioLabs tenant companies have raised over $1.7 billion dollars.

About AbbVie
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience.  In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at Follow @abbvie on Twitter, Facebook or LinkedIn.

MBC BioLabs Contact:
Linda Eng

AbbVie Contact:
Gabrielle Tarbert

Upcoming Event

  • Office Hours with WSGR Patent and Corporate Law

    To apply for Office Hours contact: Carol Ochoa Sponsored by:
    Ali Alemozafar Dr. Ali R. Alemozafar is a senior associate at Wilson Sonsini Goodrich & Rosati, where he focuses on patent prosecution, strategic patent counseling, and IP due diligence in a wide range of technical fields, including diagnostics, therapeutics, genomics, and materials. Ali received his Ph.D. in chemical engineering at Stanford University, where he investigated the reactivity and atomic-scale changes accompanying reactions on various catalysts. During his postdoctoral research fellowship at the Department of Chemistry and Chemical Biology at Harvard University, he investigated the dynamics of TiOx nanoparticles and the use of gold as an oxidation catalyst. Prior to attending law school, Ali worked on data warehousing, business intelligence, and enterprise data integration. Ali frequently lectures at the UC Berkeley School of Law and UC Hastings College of the Law on various intellectual property topics, including patent strategy and IP due diligence. Michael Hostetler Dr. Mike Hostetler is a partner in the SOMA and San Diego offices of Wilson Sonsini Goodrich & Rosati, where he provides strategic intellectual property counseling to more than 100 growth enterprises in the pharmaceutical and biotechnology, and information technology industries. He works with both venture-backed and public companies. His expertise includes patent strategy, patent prosecution, and patent diligence (both buy and sell side) for venture financings, public offerings, and mergers and acquisitions. He has provided patent counseling in support of pharmaceutical and biotechnology, and information technology products in all stages of development, from proof of concept to regulatory approval to product launch. He leads a talented team of patent associates and patent agents that can meet virtually any technical and strategic need. Mike currently serves as a member of the firm's Policy and Nominating Committees. Elton Satusky Elton Satusky is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati. He specializes in public and private corporate finance and corporate law and governance. Elton also has considerable expertise in the areas of mergers and acquisitions and venture capital.


953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287

Sign-Up for our Newsletter